EMEA-001164-PIP01-11-M04

Table of contents

Key facts

Invented name
Veyvondi
Active substance
vonicog alfa
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0463/2020
PIP number
EMEA-001164-PIP01-11-M04
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of von Willebrand disease
Route(s) of administration
Intravenous use
Contact for public enquiries
Baxalta Innovations GmbH

Tel. +800 6683 8470
E-mail: medinfoEMEA@takeda.com

 

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating